Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Conn Med ; 80(6): 359-64, 2016.
Article in English | MEDLINE | ID: mdl-27509644

ABSTRACT

Summary The Respimat SMI offers a novel delivery mechanism for the management of primarily COPD, but asthma as well. Presently, four different medications, as monotherapy or a combination of two active ingredients, are available using the Respimat SMI technology. Multiple studies have demonstrated safety and efficacy of these drugs when delivered via Respimat SMI. Patients tend to prefer the Respimat SMI over traditional inhaler devices, as it overcomes some of the disadvantages posed by traditional delivery devices.


Subject(s)
Asthma/drug therapy , Bronchodilator Agents/administration & dosage , Nebulizers and Vaporizers , Pulmonary Disease, Chronic Obstructive/drug therapy , Albuterol, Ipratropium Drug Combination/administration & dosage , Benzoxazines/administration & dosage , Drug Combinations , Equipment Design , Humans , Patient Preference , Tiotropium Bromide/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...